JP2023523584A5 - - Google Patents

Info

Publication number
JP2023523584A5
JP2023523584A5 JP2022564276A JP2022564276A JP2023523584A5 JP 2023523584 A5 JP2023523584 A5 JP 2023523584A5 JP 2022564276 A JP2022564276 A JP 2022564276A JP 2022564276 A JP2022564276 A JP 2022564276A JP 2023523584 A5 JP2023523584 A5 JP 2023523584A5
Authority
JP
Japan
Application number
JP2022564276A
Other languages
Japanese (ja)
Other versions
JPWO2021216972A5 (https=
JP2023523584A (ja
JP7791836B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/028798 external-priority patent/WO2021216972A1/en
Publication of JP2023523584A publication Critical patent/JP2023523584A/ja
Publication of JPWO2021216972A5 publication Critical patent/JPWO2021216972A5/ja
Publication of JP2023523584A5 publication Critical patent/JP2023523584A5/ja
Application granted granted Critical
Publication of JP7791836B2 publication Critical patent/JP7791836B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022564276A 2020-04-24 2021-04-23 抗cd3抗体及びその使用 Active JP7791836B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063015149P 2020-04-24 2020-04-24
US63/015,149 2020-04-24
PCT/US2021/028798 WO2021216972A1 (en) 2020-04-24 2021-04-23 Anti-cd3 antibodies and uses thereof

Publications (4)

Publication Number Publication Date
JP2023523584A JP2023523584A (ja) 2023-06-06
JPWO2021216972A5 JPWO2021216972A5 (https=) 2024-05-02
JP2023523584A5 true JP2023523584A5 (https=) 2024-05-02
JP7791836B2 JP7791836B2 (ja) 2025-12-24

Family

ID=78270196

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022564276A Active JP7791836B2 (ja) 2020-04-24 2021-04-23 抗cd3抗体及びその使用

Country Status (6)

Country Link
US (1) US20230212289A1 (https=)
EP (1) EP4139347A4 (https=)
JP (1) JP7791836B2 (https=)
CN (1) CN115803340A (https=)
CA (1) CA3176391A1 (https=)
WO (1) WO2021216972A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
US11912771B2 (en) 2021-03-09 2024-02-27 Cdr-Life Ag MAGE-A4 peptide-MHC antigen binding proteins
EP4304725A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Rabbit-derived antigen binding protein nucleic acid libraries
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
WO2023205733A1 (en) * 2022-04-21 2023-10-26 Academia Sinica Genetically engineered innate lymphoid cells for enhancing lifespan and/or treating cancers
US20260042860A1 (en) * 2022-08-04 2026-02-12 Memorial Sloan-Kettering Cancer Center Anti-cd24 antibodies and uses thereof
KR20250067130A (ko) 2022-09-14 2025-05-14 씨디알-라이프 아게 Mage-a4 펩티드 이중 t 세포 연결체
WO2024199454A1 (en) * 2023-03-29 2024-10-03 Nanjing GenScript Biotech Co., Ltd. Antibodies and variants thereof against human cluster of differentiation 3 protein
CN116574182B (zh) * 2023-06-09 2024-02-06 上海交通大学医学院附属第九人民医院 一种抗人Ki-67抗体及其制备方法和用途
CN121293363B (zh) * 2025-12-09 2026-04-21 上海玄言生物科技有限公司 一种靶向cd14和cd3的双功能t细胞衔接器及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0720565A2 (pt) * 2006-12-20 2013-09-17 Mmr Information Systems Inc anticorpos e mÉtodos para a sua preparaÇço e seu uso
CN102796199A (zh) * 2011-05-26 2012-11-28 中国医学科学院血液病医院 抗CD3抗体Fv片段与白介素3融合蛋白突变体、制备方法及其用途
EP2892924B1 (en) * 2012-06-14 2020-11-25 Therapix Biosciences Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
CN103173478B (zh) * 2013-03-04 2015-09-09 西北大学 一种携带ptd的抗人cd3单链抗体的制备方法
CN103467605B (zh) * 2013-09-05 2015-02-04 武汉友芝友生物制药有限公司 一种cd3抗原及其制备方法和用途
US20160326249A1 (en) * 2014-01-15 2016-11-10 Zymeworks Inc. Bi-specific cd3 and cd19 antigen-binding constructs
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
RU2020122439A (ru) * 2014-11-24 2020-09-24 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3
US11046768B2 (en) 2017-01-27 2021-06-29 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
KR20190140943A (ko) * 2017-04-24 2019-12-20 메모리얼 슬로안 케터링 캔서 센터 항-cd33 항체 제제
US20180371088A1 (en) * 2017-06-22 2018-12-27 Development Center For Biotechnology TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT AND USES THEREOF IN CANCER THERAPY
MX2020009774A (es) * 2018-03-21 2020-10-08 Alx Oncology Inc Anticuerpos contra proteína alfa reguladora de señal y métodos de uso.
EP3802595A1 (en) * 2018-06-07 2021-04-14 OncoOne Research & Development GmbH Anti-oxmif/anti-cd3 antibody for cancer treatment
WO2020062155A1 (en) 2018-09-29 2020-04-02 Mab-Legend Biotech Co., Ltd. Dual targeting antigen binding molecule
CN110964114B (zh) 2018-09-29 2023-07-04 上海博槿生物科技有限公司 一种双靶点抗原结合分子

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
JP2023523584A5 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)